Transfluvac

Transfluvac is a non-adjuvanted, inactivated monovalent influenza A (H1N1pdm2009) vaccine developed by the French National Institute of Health and Medical Research (INSERM). It contains the inactivated influenza A (H1N1) pandemic 2009 virus antigen (hemagglutinin) and is designed to elicit hemagglutination-inhibition (HI) antibodies and anti-HA specific T-cell responses. Transfluvac was evaluated in a Phase II clinical trial (INSERM C09-32, NCT01086904) in France to assess its humoral immunogenicity, safety, and tolerability in adult renal transplant recipients who are immunocompromised due to triple immunosuppressive therapy. The vaccine is administered intramuscularly as a two-dose regimen 21 days apart.